Introgen Therapeutics, Inc. Announces Oral Health Alliance With Colgate-Palmolive Using Introgen's Molecular Therapies
November 04 2005 - 9:00AM
PR Newswire (US)
$20 Million Transaction Will Target Treatment and Prevention of
Oral Cancer and Oral Premalignancies AUSTIN, Texas, Nov. 4
/PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (NASDAQ:INGN)
today announced an alliance with Colgate-Palmolive Company
(NYSE:CL) to develop and potentially market oral health care
products. The terms of the alliance call for the development of
specialized formulations of Introgen's molecular therapies targeted
at pre-cancerous conditions of the oral cavity and oral cancer.
Colgate-Palmolive has today purchased $20 million of Introgen
shares and has priority rights regarding products that may be
developed by the alliance. Research and development activities in
the alliance will be conducted by Introgen and will focus on oral
formulations of Introgen's molecular therapeutics employing tumor
suppressors such as p53, mda-7, and FUS1. Introgen academic
collaborators are conducting a phase 1/2 clinical study using INGN
234, a mouthwash formulation delivering the p53 tumor suppressor
for oral cancer prevention in patients diagnosed with leukoplakia,
a pre-cancerous condition that can lead to oral cancer. Leukoplakia
is usually diagnosed by dentists and, according to the journal
Practical Periodontics and Aesthetic Dentistry, occurs in
approximately 3 percent of the adult population. "We are
enthusiastic about the opportunity to apply Introgen's molecular
agents to develop oral care products with Colgate-Palmolive,"
stated David G. Nance, Chief Executive Officer of Introgen. "We
believe future commercial applications of therapeutic genes will
include topical formulations such as those developed for oral use
under the alliance with Colgate. The tissues lining the oral cavity
may be particularly well suited and accessible targets for
molecular therapies that can arrest abnormal cell growth without
harming normal cells. We believe that repair of damaged cells and
safe elimination of malignant or pre-malignant cells from the mouth
could represent important therapies for dentists, oral health
professionals and oncology specialists to prevent and treat oral
diseases. We expect to investigate new formulations of oral rinses,
gels or other topically applied products under the Colgate
alliance." Excluded from the alliance with Colgate are Introgen's
current portfolio of cancer product candidates, i.e. ADVEXIN, INGN
241, INGN 225, and INGN 401. Introgen Therapeutics, Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted molecular therapies for the treatment
of cancer and other diseases. Introgen is developing molecular
therapeutics, immunotherapies, vaccines and nano-particle tumor
suppressor therapies to treat a wide range of cancers and
hyper-proliferative disorders using tumor suppressors, cytokines,
proteins and genes. Introgen maintains integrated research,
development, manufacturing, clinical and regulatory departments and
operates multiple manufacturing facilities including a commercial
scale cGMP manufacturing facility. For more information on Introgen
Therapeutics, or for a menu of archived press releases, please
visit Introgen's Website at: http://www.introgen.com/ Statements in
this release that are not strictly historical may be
"forward-looking" statements, including those relating to
Introgen's future success with its clinical development program for
treatment of cancer or other diseases and the development by
Introgen Therapeutics, Inc. of its molecular therapies targeted at
oral cancer and pre-cancerous conditions of the oral cavity in
connection with the alliance with Colgate-Palmolive. The actual
results may differ from those described in this release due to
risks and uncertainties that exist in Introgen's operations and
business environment, including Introgen's stage of product
development and the limited experience in the development of
gene-based drugs in general, dependence upon proprietary technology
and the current competitive environment, history of operating
losses and accumulated deficits, reliance on collaborative
relationships, and uncertainties related to clinical trials, the
safety and efficacy of Introgen's product candidates, the ability
to obtain the appropriate regulatory approvals, Introgen's patent
protection and market acceptance, as well as other risks detailed
from time to time in Introgen's filings with the Securities and
Exchange Commission including its filings on Form 10-K and Form
10-Q. Introgen undertakes no obligation to publicly release the
results of any revisions to any forward-looking statements that
reflect events or circumstances arising after the date hereof.
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708
9310 Ext. 322 Email: DATASOURCE: Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,
+1-512-708-9310, ext. 322, or Web site: http://www.introgen.com/
Copyright
Colgate Palmolive (NYSE:CL)
Historical Stock Chart
From May 2024 to Jun 2024
Colgate Palmolive (NYSE:CL)
Historical Stock Chart
From Jun 2023 to Jun 2024